Regulatory timeline
Federal safety actions on COVID-19 vaccines, in order: signals, pauses, recommendations, warnings, label changes, restrictions and withdrawals — with whether each is still current, was superseded, or was a signal later evaluation did not confirm. A preliminary signal is never shown as an established finding.
Topic: All · Myocarditis and pericarditis · Blood clots and thrombosis with thrombocytopenia (TTS) · Stroke · Guillain-Barré syndrome
Agency: FDA · CDC
Threads: janssen tts · janssen gbs · stroke signal
-
CDC and FDA recommend pausing the Janssen (J&J) vaccine after rare clots with low platelets
Product: Janssen (Johnson & Johnson) COVID-19 vaccine · Population: All recipients
What changed: Use paused while six reported cases of cerebral venous sinus thrombosis with low platelets were reviewed.
CDC and FDA recommended pausing the vaccine “out of an abundance of caution” while reviewing six U.S. reports of cerebral venous sinus thrombosis with thrombocytopenia among more than 6.8 million doses.
A pause to investigate is not a finding that the vaccine caused the events.
-
FDA and CDC lift the Janssen pause and add a clotting warning
Product: Janssen (Johnson & Johnson) COVID-19 vaccine · Population: All recipients
What changed: Use resumed; fact sheets updated with information on the risk of thrombosis with thrombocytopenia.
After two ACIP meetings and a safety review, the agencies lifted the pause and added information about the rare clotting risk to the vaccine's fact sheets.
Superseded by the May 2022 restriction.
Later: FDA restricted the vaccine's use on May 5, 2022.
-
Guillain-Barré syndrome warning added for the Janssen vaccine; ACIP reaffirms its use
Product: Janssen (Johnson & Johnson) COVID-19 vaccine · Population: Adult recipients
What changed: Fact sheets revised to describe an observed increased risk of Guillain-Barré syndrome in the 42 days after vaccination.
FDA revised the Janssen fact sheets to note an observed increased risk of Guillain-Barré syndrome in the 42 days after vaccination; ACIP reviewed the data and concluded benefits outweighed risks.
Superseded by the 2022 restriction and the 2023 revocation of the Janssen authorization.
Later: The Janssen authorization was restricted in 2022 and revoked in 2023.
-
CDC adopts ACIP's preference for mRNA vaccines over the Janssen vaccine
Product: Janssen (Johnson & Johnson) COVID-19 vaccine · Population: Adults
What changed: Recommendation changed to prefer mRNA vaccines, citing thrombosis with thrombocytopenia syndrome.
ACIP recommended mRNA vaccines over the Janssen vaccine for adults, citing the risk of thrombosis with thrombocytopenia syndrome; CDC adopted the recommendation.
Superseded by the 2022 FDA restriction.
Later: FDA restricted the vaccine's use on May 5, 2022.
-
CDC and FDA report a preliminary ischemic-stroke signal for Pfizer's bivalent booster in people 65+
Product: Pfizer-BioNTech COVID-19 Vaccine, Bivalent · Population: People 65 and older
What changed: No change to recommendations; the signal was investigated in other databases.
CDC's Vaccine Safety Datalink flagged a possible increase in ischemic stroke 1–21 days after Pfizer's bivalent booster in people 65 and older. Medicare and VA analyses did not find an increased risk, and as data accumulated the agencies said the evidence did not support a safety issue.
A preliminary signal from near-real-time surveillance is not a finding; this one was not confirmed by other systems.
Thread: janssen tts
- Pause — CDC and FDA recommend pausing the Janssen (J&J) vaccine after rare clots with low platelets Lifted
- Warning — FDA and CDC lift the Janssen pause and add a clotting warning Superseded
- Recommendation — CDC adopts ACIP's preference for mRNA vaccines over the Janssen vaccine Superseded
Thread: janssen gbs
- Warning — Guillain-Barré syndrome warning added for the Janssen vaccine; ACIP reaffirms its use Superseded
Thread: stroke signal
- Signal — CDC and FDA report a preliminary ischemic-stroke signal for Pfizer's bivalent booster in people 65+ Signal not confirmed